Agena
Mesa Laboratories Acquires Agena Bioscience for $300M
Agena is expected to add between $63 million and $67 million to Mesa's revenues during the first year of ownership, excluding COVID-related revenues.
Ethos Labs, Agena Biosciences Partner on SARS-CoV-2 Variant Identification
Ethos said Agena's MALDI-TOF-based MassArray system will allow for more rapid and lower-cost detection of SARS-Cov-2 variants than next-generation sequencing.
Agena Inks MassArray Distribution Deal for Middle East, Africa, Central Asia
The deal covers Agena's MassArray platform for genetic variant measurement, as well as genetic testing applications and other related products.
Agena Bioscience Gets FDA Emergency Use Authorization for MassArray Coronavirus Test
The company's RT-PCR/MALDI-TOF test comprises five assays designed to detect the N, ORF1, and ORF1ab regions of the SARS-CoV-2 genome.
The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.